Sirtris Pharmaceuticals of Cambridge, MA has gained $37 million in new funding, including $22 million in venture funds and $15 million in venture debt. The third round was led by new investor Bessemer Venture Partners and included Genzyme Ventures, among others. "Adding the expertise of a world class biopharmaceutical organization like Genzyme and the insight of leading investors like Bessemer and QVT further strengthens our ability to develop a new class of drugs to treat diseases of aging," said Christoph Westphal, M.D., Ph.D., CEO of Sirtris.
- read the release